SFEBES2018 Poster Presentations Neuroendocrinology and pituitary (25 abstracts)
Prolactin as a surrogate marker of prolactinoma diagnosis in PCOS
Georgios K Dimitriadis 1, , Eleni Magdalini Kyritsi 1 , Anna Angelousi 3 , Hiten Mehta 4 , Amjad Shad 5 , Maria Mytilinaiou 1 , Gregory Kaltsas 1 & Harpal S Randeva 1,
1Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK; 2Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK; 3Department of Pathophysiology, National & Kapodistrian University of Athens, Coventry, UK; 4Department of Radiology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK; 5Department of Neurosurgery, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
Background: To identify a serum prolactin (PRL) cut-off value indicative of a PRL-producing adenoma in women with polycystic ovarian syndrome (PCOS) and hyperprolactinaemia and characterize such patients. Materials and methods: In the present retrospective case–control study, the medical records of 528 PCOS women were reviewed. Pituitary magnetic resonance imaging (MRI) was performed in PCOS patients with PRL levels ≥94.0 ng/ml and/or symptoms suspicious of a pituitary adenoma (PA). Prolactinoma diagnosis was made in the presence of an MRI-identifiable PA with biochemical and radiological response to dopamine agonists. Receiver operating characteristic (ROC) curve analysis was performed to determine a serum PRL threshold that could identify hyperprolactinaemic PCOS subjects with prolactinomas. Clinical, metabolic and endocrine parameters were also analysed.
Results: Among 528 patients with PCOS, 60 (11.4%) had elevated PRL levels. Of 44 (73.3%) patients who had pituitary imaging, 19 had PAs, 18 normal MRI and seven other abnormalities. Patients harbouring prolactinomas had significantly higher PRL levels compared to patients without adenomas (median PRL 95.4 vs 49.2 ng/ml, P < .0001). A PRL threshold of 85.2 ng/ml could distinguish patients with prolactinomas with 77% sensitivity and 100% specificity (Area Under the curve (AUC) (95%) 0.91(0.8–1.018), P=.0001). PCOS women with prolactinomas were younger and had lower LH levels compared to women without prolactinomas.
Conclusions: In women with PCOS, PRL levels exceeding 85.2 ng/ml are highly suggestive of a prolactinoma warranting pituitary imaging. Pituitary MRI could also be considered in young PCOS patients with milder PRL elevation and low LH levels.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more